Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT02482454
PHASE2/PHASE3

Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma

Sponsor: The First People's Hospital of Changzhou

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with cholangiocarcinoma.

Official title: Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma

Key Details

Gender

All

Age Range

30 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2012-07

Completion Date

2033-07

Last Updated

2017-08-01

Healthy Volunteers

No

Interventions

PROCEDURE

Radiofrequency ablation

Radiofrequency ablation is performed percutaneously under CT/US guidance

BIOLOGICAL

Cytokine-induced killer cells

The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.

Locations (1)

The First People's Hospital of Changzhou

Changzhou, Jiangsu, China